{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T18:03:15Z","timestamp":1790532195759,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejpn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Paediatric Neurology"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.ejpn.2021.03.013","type":"journal-article","created":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T13:20:19Z","timestamp":1617196819000},"page":"66-72","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Early initiation of ambroxol treatment diminishes neurological manifestations of type 3 Gaucher disease: A long-term outcome of two siblings"],"prefix":"10.1016","volume":"32","author":[{"given":"Danijela Petkovi\u0107","family":"Ramad\u017ea","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marija","family":"Zeku\u0161i\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"\u017digman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"\u0160kari\u010di\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Bogdani\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordana","family":"Musta\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"Bo\u0161njak-Na\u0111","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ozreti\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kousaku","family":"Ohno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ksenija","family":"Fumi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivo","family":"Bari\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpn.2021.03.013_bib1","first-page":"72","article-title":"Gaucher disease: the metabolic defect, pathophysiology, phenotypes and natural history","volume":"12","author":"Baris","year":"2014","journal-title":"Pediatr. Endocrinol. Rev."},{"key":"10.1016\/j.ejpn.2021.03.013_bib2","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ymgme.2004.08.015","article-title":"Gaucher disease: complexity in a \"simple\" disorder","volume":"83","author":"Sidranski","year":"2014","journal-title":"Mol. Genet. Metabol."},{"key":"10.1016\/j.ejpn.2021.03.013_bib3","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s10545-009-9009-6","article-title":"Neuronopathic gaucher disease: demographic and clinical features of 131 patients enrolled in the international collaborative gaucher group neurological outcomes subregistry","volume":"33","author":"Tylki-Szyma\u0144ska","year":"2010","journal-title":"J.\u00a0Inherit. Metab. Dis."},{"key":"10.1016\/j.ejpn.2021.03.013_bib4","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1067\/S0022-3476(03)00302-0","article-title":"Phenotypic continuum in neuronopathic Gaucher disease: an intermediate phenotype between type 2 and type 3","volume":"143","author":"Goker-Alpan","year":"2003","journal-title":"J.\u00a0Pediatr."},{"key":"10.1016\/j.ejpn.2021.03.013_bib5","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3390\/diseases5010010","article-title":"The spectrum of neurological manifestations associated with Gaucher disease","volume":"5","author":"Roshan Lal","year":"2017","journal-title":"Diseases"},{"key":"10.1016\/j.ejpn.2021.03.013_bib6","first-page":"73","article-title":"Characteristics of 26 patients with type 3 Gaucher disease: a descriptive analysis from the Gaucher Outcome Survey","volume":"14","author":"Schwartz","year":"2017","journal-title":"Mol Genet Metab Rep"},{"key":"10.1016\/j.ejpn.2021.03.013_bib7","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1086\/302925","article-title":"Analysis and classification of 304 mutant alleles in patients with type 1 and type 3 Gaucher disease","volume":"66","author":"Koprivica","year":"2000","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ejpn.2021.03.013_bib8","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.bcmd.2010.10.007","article-title":"A\u00a0monozygotic twin pair with highly discordant Gaucher phenotypes","volume":"46","author":"Biegstraaten","year":"2011","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.ejpn.2021.03.013_bib9","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1007\/s10545-009-1164-2","article-title":"Management of neuronopathic gaucher disease: revised recommendations","volume":"32","author":"Vellodi","year":"2009","journal-title":"J.\u00a0Inherit. Metab. Dis."},{"key":"10.1016\/j.ejpn.2021.03.013_bib10","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3109\/08880018.2012.762076","article-title":"Gauchers Disease-A reappraisal of hematopoietic stem cell transplantation","volume":"30","author":"Ito","year":"2013","journal-title":"Pediatr. Hematol. Oncol."},{"key":"10.1016\/j.ejpn.2021.03.013_bib11","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3109\/08880018.2013.793757","article-title":"Allogeneic hematopoietic stem cell transplantation for treatment of Gaucher disease","volume":"20","author":"Machaczka","year":"2013","journal-title":"Pediatr. Hematol. Oncol."},{"key":"10.1016\/j.ejpn.2021.03.013_bib12","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/ana.21491","article-title":"Randomized, controlled trial of miglustat in Gaucher's disease type 3","volume":"64","author":"Schiffmann","year":"2008","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ejpn.2021.03.013_bib13","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1042\/ETLS20180058","article-title":"Substrate reduction therapy for inborn errors of metabolism","volume":"3","author":"Yue","year":"2019","journal-title":"Emerging Topics in Life Sci"},{"key":"10.1016\/j.ejpn.2021.03.013_bib14","doi-asserted-by":"crossref","first-page":"23502","DOI":"10.1074\/jbc.M109.012393","article-title":"Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease","volume":"284","author":"Maegawa","year":"2009","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejpn.2021.03.013_bib15","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.braindev.2012.05.008","article-title":"The chaperone activity and toxicity of ambroxol on Gaucher cells and normal mice","volume":"35","author":"Luan","year":"2013","journal-title":"Brain Dev."},{"key":"10.1016\/j.ejpn.2021.03.013_bib16","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/acn3.292","article-title":"Ambroxol chaperone therapy for neuronopathic Gaucher disease: a pilot study","volume":"3","author":"Narita","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.ejpn.2021.03.013_bib17","doi-asserted-by":"crossref","first-page":"5","DOI":"10.15557\/JoU.2018.0001","article-title":"The relationship between splenic length in healthy children from the Eastern Anatolia Region and sex, age, body height and weight","volume":"18","author":"\u00d6zdikici","year":"2018","journal-title":"J\u00a0Ultrason"},{"key":"10.1016\/j.ejpn.2021.03.013_bib18","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3126\/kumj.v13i4.16825","article-title":"Sonographic assessment of the normal dimensions of liver, spleen, and kidney in healthy children at tertiary care hospital","volume":"13","author":"Thapa","year":"2015","journal-title":"Kathmandu Univ. Med. J."},{"key":"10.1016\/j.ejpn.2021.03.013_bib20","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1399-0004.1978.tb04242.x","article-title":"Synthetic substrate \u03b2-glucoside activity in leukocyte: a reproducible method for the identification of the patients and carriers of Gaucher disease","volume":"13","author":"Wenger","year":"1978","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ejpn.2021.03.013_bib21","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1172\/JCI117084","article-title":"Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease","volume":"93","author":"Hollak","year":"1994","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ejpn.2021.03.013_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0079732","article-title":"Glucosylsphingosine is a highly sensitive and specific biomarker for primary diagnostic and follow-up monitoring in Gaucher disease in a non-Jewish, Caucasian cohort of Gaucher disease patients","volume":"8","author":"Rolfs","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.ejpn.2021.03.013_bib23","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/humu.20776","article-title":"Haplotype analysis suggests a single balkan origin for the Gaucher disease [D409H;H255Q] double mutant allele","volume":"29","author":"Santamaria","year":"2008","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ejpn.2021.03.013_bib24","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1136\/jmedgenet-2019-106132","article-title":"Pharmacologic properties of high-dose Ambroxol in four fatients with Gaucher disease and myoclonic epilepsy","volume":"57","author":"Kim","year":"2020","journal-title":"J.\u00a0Med. Genet."},{"key":"10.1016\/j.ejpn.2021.03.013_bib25","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.bcmd.2016.12.001","article-title":"The additive effect on the antiepileptic treatment of ambroxol in type 3 gaucher patient. The early observation","volume":"68","author":"Pawlinski","year":"2018","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.ejpn.2021.03.013_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcmd.2019.102402","article-title":"Early initiation of high-dose oral ambroxol in combination with enzyme replacement therapy in a neuropathic Gaucher infant","volume":"81","author":"Chu","year":"2020","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.ejpn.2021.03.013_bib27","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1203\/01.PDR.0000049515.79882.94","article-title":"Myoclonic epilepsy in Gaucher disease: genotype-phenotype insights from a rare patient subgroup","volume":"53","author":"Park","year":"2003","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.ejpn.2021.03.013_bib28","first-page":"733","article-title":"Tricuspid atresia and Gaucher's disease","volume":"16","author":"Sabatini","year":"1961","journal-title":"Pediatrie"},{"key":"10.1016\/j.ejpn.2021.03.013_bib29","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3233\/JAD-2012-120931","article-title":"Extreme stability of chitotriosidase in cerebrospinal fluid makes it a suitable marker for microglial activation in clinical trials","volume":"32","author":"Olsson","year":"2012","journal-title":"J\u00a0Alzheimers Dis"},{"key":"10.1016\/j.ejpn.2021.03.013_bib30","article-title":"Effect of ambroxol chaperone therapy on glucosylsphingosine (Lyso-Gb1) levels in two Canadian patients with type 3 Gaucher disease","volume":"20","author":"Charkhand","year":"2019","journal-title":"Mol. Genet. Metabol."}],"container-title":["European Journal of Paediatric Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090379821000805?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090379821000805?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T18:37:47Z","timestamp":1761071867000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1090379821000805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":29,"alternative-id":["S1090379821000805"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpn.2021.03.013","relation":{},"ISSN":["1090-3798"],"issn-type":[{"value":"1090-3798","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early initiation of ambroxol treatment diminishes neurological manifestations of type 3 Gaucher disease: A long-term outcome of two siblings","name":"articletitle","label":"Article Title"},{"value":"European Journal of Paediatric Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpn.2021.03.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}